This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

A new targeted therapy aimed specifically at FGFR3, TYRA-300, is showing preliminary promise in patients with advanced FGFR3-altered bladder cancer. Partial responses have been seen in an ongoing ...

According to research presented at the Society for the Immunotherapy of Cancer Annual Meeting in Houston, TX, the IL15 agonist NKTR-255 (Nektar Therapeutics) reverses lymphopenia caused by ...

1State Key Laboratory of Genetic Engineering, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Cancer Institutes, Shanghai, ...

Institute of TCM-X/MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist/Department of Automation, Tsinghua University, Beijing, China.

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

Mol Cancer Ther (2024) 23 (11): 1515.

1Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.

The sequencing of EGFR 40 years ago and the discovery of EGFR mutations 20 years ago revolutionized lung cancer treatment by enabling the development of targeted therapies and significantly improving ...

1Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.

1Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science ...